Literature DB >> 2817800

Antitumoral effects of lipopolysaccharides, tumor necrosis factor, interferon and activated macrophages: synergism and tissue distribution.

M Chokri1, M Freudenberg, C Galanos, P Poindron, J Bartholeyns.   

Abstract

Treatment of C57BL/6 mice bearing Lewis lung carcinoma or of BALB/c mice bearing EMT6 sarcoma with tumor necrosis factor (TNF), lipopolysaccharides (LPS) or interferon caused necrosis of the solid tumors and regression. Toxicity was observed in tumor-bearing animals when TNF or LPS were used at effective antitumoral doses. Similar antitumoral effects could be achieved using less than 1 million macrophages from C57BL/6, lung of from BALB/c peritoneal cavity expanded in vitro, and spontaneously fully activated to cytotoxicity during culture. This effect, observed after transfer twice a week by intravenous or peritumoral route, was not dependent on histocompatibility. Additive effects were observed after combined treatment with activated macrophages and a low dose of LPS or TNF. The biodistribution of labelled LPS and of labelled cytotoxic macrophages was studied in tumor-bearing mice. Although, as expected, LPS was concentrated essentially in the liver, a slow accumulation in the center of the tumor was observed. Macrophages injected intravenously accumulated in the lung and were then redistributed towards liver, kidney and the tumor periphery. Macrophages injected locally remained essentially in the tumor periphery with a slow redistribution in the body. The complementary localization of LPS and of cytotoxic macrophages respectively in the center and periphery of solid tumors might explain their synergism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2817800

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Effect of chelerythrine against endotoxic shock in mice and its modulation of inflammatory mediators in peritoneal macrophages through the modulation of mitogen-activated protein kinase (MAPK) pathway.

Authors:  Weifeng Li; Ting Fan; Yanmin Zhang; Xiaofeng Niu; Wei Xing
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

2.  Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer.

Authors:  F Pagès; S Lebel-Binay; A Vieillefond; L Deneux; M Cambillau; O Soubrane; B Debré; D Tardy; J-L Romet Lemonne; J-P Abastado; W-H Fridman; N Thiounn
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

3.  Osteoinductive LIM mineralization protein-1 suppresses activation of NF-kappaB and selectively regulates MAPK pathways in pre-osteoclasts.

Authors:  Hui Liu; Maggie Bargouti; Susu Zughaier; Zhaomin Zheng; Yunshan Liu; Sreedhara Sangadala; Scott D Boden; Louisa Titus
Journal:  Bone       Date:  2009-11-18       Impact factor: 4.398

4.  Protein phosphorylation in murine peritoneal macrophages induced by infection with Salmonella species.

Authors:  S Saito; H Shinomiya; M Nakano
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

5.  Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects.

Authors:  A Faradji; A Bohbot; M Schmitt-Goguel; N Roeslin; S Dumont; M L Wiesel; C Lallot; M Eber; J Bartholeyns; P Poindron
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Similar mechanisms of action of defined polysaccharides and lipopolysaccharides: characterization of binding and tumor necrosis factor alpha induction.

Authors:  M Otterlei; A Sundan; G Skjåk-Braek; L Ryan; O Smidsrød; T Espevik
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

7.  Immunomodulatory effects of polar lichens on the function of macrophages in vitro.

Authors:  Hye-Sook Choi; Joung Han Yim; Hong Kum Lee; Suhkneung Pyo
Journal:  Mar Biotechnol (NY)       Date:  2008-07-09       Impact factor: 3.619

8.  Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.

Authors:  T Yamazaki; D Hannani; V Poirier-Colame; S Ladoire; C Locher; A Sistigu; N Prada; S Adjemian; J P P Catani; M Freudenberg; C Galanos; F André; G Kroemer; L Zitvogel
Journal:  Cell Death Differ       Date:  2013-06-28       Impact factor: 15.828

9.  Interactions between human macrophages and tumor cells in three-dimensional cultures.

Authors:  R Audran; L Dazord; L Toujas
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

10.  Interactions between rnacrophage cytokines and eicosanoids in expression of antitumour activity.

Authors:  S Ben-Efraim
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.